当前位置： SCI文献检索 > Clinical Lung Cancer期刊下所有文献 > Pulmonary function tests as a predictor of quantitative and qualitative outcomes after thoracic surgery for lung cancer.

Pulmonary function tests as a predictor of quantitative and qualitative outcomes after thoracic surgery for lung cancer.

Abstract：

BACKGROUND:Pulmonary function tests are used to select patients with non-small-cell lung cancer (NSCLC) suitable for thoracic surgery. We studied the impact of pulmonary function tests on both quantitative (morbidity, mortality, and overall survival [OS]) and qualitative (quality of life [QOL]) outcomes of patients undergoing thoracic surgery for NSCLC. PATIENTS AND METHODS:Patients with proven or highly probable NSCLC referred for thoracic surgery were eligible. The postoperative outcomes morbidity, 90-day mortality, OS, and QOL based on PGWBI and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 were studied according to the results of the preoperative pulmonary function tests (forced expiratory volume in 1 second [FEV(1)]; vital capacity, residual volume, total lung capacity, airways resistance, diffusing capacity corrected for alveolar volume). RESULTS:A total of 110 patients were studied, with 94 patients eligible for analysis. Postoperative mortality and morbidity affected 9.5% and 40% of patients, respectively. These patients presented with significantly lower preoperative values of vital capacity, total lung capacity, and diffusing capacity corrected for alveolar volume and higher preoperative values of airways resistance compared with patients with an uncomplicated postoperative course. Better survival was correlated with higher preoperative values of FEV(1), vital capacity, total lung capacity, and a lower pulmonary distension, especially when expressed as a percentage of predicted value. None of the postoperative QOL scores was influenced by preoperative pulmonary function tests results. CONCLUSION:Pulmonary function tests allow a relatively good prediction of postoperative quantitative outcomes such as postoperative morbidity and mortality as well as OS after thoracic surgery for NSCLC. However, pulmonary function tests remain poorly correlated to postoperative qualitative outcomes, making QOL a separate and essential assessment of the health status of patients with resected NSCLC.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Greillier L,Thomas P,Loundou A,Doddoli C,Badier M,Auquier P,Barlési F

doi

10.3816/CLC.2007.n.042

subject

Has Abstract

pub_date

2007-11-01 00:00:00

pages

554-61

issue

9

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(11)70836-1

journal_volume

8

pub_type

杂志文章

相关文献

Clinical Lung Cancer文献大全
  • Prognostic Impact and Risk Factors of Immune-Related Pneumonitis in Patients With Non-Small-Cell Lung Cancer Who Received Programmed Death 1 Inhibitors.

    abstract：INTRODUCTION:Pneumonitis is one of the immune-related adverse events of programmed death 1 (PD-1) inhibitors that sometimes cause lethal outcomes. Although some recent reports have described PD-1 inhibitors as more effective in non-small-cell lung cancer (NSCLC) patients with immune-related adverse events than in those...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,多中心研究

    doi：10.1016/j.cllc.2019.07.006

    authors： Fukihara J,Sakamoto K,Koyama J,Ito T,Iwano S,Morise M,Ogawa M,Kondoh Y,Kimura T,Hashimoto N,Hasegawa Y

    更新日期：2019-11-01 00:00:00

  • Combined-modality therapy for inoperable non-small-cell lung cancer using gemcitabine.

    abstract：:Combined-modality therapy with chemotherapy and radiation appears to be the most efficacious therapeutic modality for patients with locally advanced non-small-cell lung cancer. Most of the trials exploring this approach have utilized older agents such as cisplatin, vinblastine, and etoposide. Recent data suggest that ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2002.s.003

    authors： Curran WJ Jr

    更新日期：2002-03-01 00:00:00

  • Analysis of lung cancer patients enrolled in CTEP (cancer therapy evaluation program)-sponsored phase I trials.

    abstract：INTRODUCTION:A recent review of phase I trials suggests that participation in these trials can be associated with clinical benefit and the rate of drug-related deaths is low. We conducted an analysis of the Cancer Therapy Evaluation Program (CTEP)-sponsored phase I trials to assess the outcomes of lung cancer patients ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.03.022

    authors： Gadgeel SM,Ivy P,Chen W,Mauer J,Smith D,Lorusso P

    更新日期：2011-07-01 00:00:00

  • The emerging role of biomarkers in advanced non-small-cell lung cancer.

    abstract：:Novel therapies, particularly those that target vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR), have improved the treatment of advanced non-small-cell lung cancer (NSCLC). The search continues for biomarkers that can predict which patients are most likely to benefit from these th...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2010.n.019

    authors： Socinski MA

    更新日期：2010-05-01 00:00:00

  • Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.

    abstract：BACKGROUND:This study assesses the predictive and prognostic roles of serum soluble intercellular adhesion molecule-1 (sICAM-1) and vascular endothelial growth factor (VEGF) during chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Changes in serum levels of sICAM-1 and VEG...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.03.009

    authors： Qian Q,Zhan P,Yu L,Shi Y,Cheng J,Wei S,Wang Q,Song Y

    更新日期：2011-03-01 00:00:00

  • First-line chemotherapy for advanced-stage non-small-cell lung cancer: focus on docetaxel.

    abstract：:Systemic chemotherapy results in modest improvements in survival and quality of life for patients with advanced-stage non-small-cell lung cancer (NSCLC). Administration of a platinum compound in combination with a taxane (paclitaxel or docetaxel), gemcitabine, vinorelbine, or irinotecan is considered optimal first-lin...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/clc.2005.s.014

    authors： Ramalingam S

    更新日期：2005-12-01 00:00:00

  • Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.

    abstract：INTRODUCTION:The effect of local therapy (LT) for oligoprogressive epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) has not been well established. Forty-six patients with stage IIIB/IV EGFR-mutated NSCLC were treated by LT and continuing tyrosine kinase inhibitors (TKIs) for oligoprogr...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.04.002

    authors： Qiu B,Liang Y,Li Q,Liu G,Wang F,Chen Z,Liu M,Zhao M,Liu H

    更新日期：2017-11-01 00:00:00

  • EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.

    abstract：INTRODUCTION:Continuing tyrosine kinase inhibitor (TKI) therapy may be beneficial when patients with non-small-cell lung cancer and EGFR mutations experience gradual disease progression after initial EGFR-TKI treatment. We aimed to compare the efficacy of simultaneous EGFR-TKI and chemotherapy with that of sequential t...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.06.005

    authors： Chang Q,Xu J,Qiang H,Teng J,Qian J,Lv M,Zhang Y,Lou Y,Zhao Y,Zhong R,Han B,Chu T

    更新日期：2020-07-06 00:00:00

  • Management of Resistance to Crizotinib in Anaplastic Lymphoma Kinase-Positive Non-Small-cell Lung Cancer.

    abstract：:During the past decade, the recognition of an ever-expanding list of driver oncogenic mutations in non-small-cell lung cancer has resulted in rapid therapeutic advances. Since the first description of the echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase (EML4-ALK) rearrangement in 4% of case...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2016.05.006

    authors： Matikas A,Kentepozidis N,Georgoulias V,Kotsakis A

    更新日期：2016-11-01 00:00:00

  • Recurrent bronchial epithelial-myoepithelial carcinoma after local therapy.

    abstract：:We present a rare case of recurrent multiple lesions of bronchial epithelial-myoepithelial carcinoma in a 74-year-old man treated with local resection. Two cellular types were found: epithelial cells and myoepithelial cells. The patient remains asymptomatic at 4-years of follow-up, supporting the fact that epithelial-...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2007.n.020

    authors： Muslimani AA,Kundranda M,Jain S,Daw HA

    更新日期：2007-05-01 00:00:00

  • Disparities in the Management of Patients With Stage I Small Cell Lung Carcinoma (SCLC): A Surveillance, Epidemiology and End Results (SEER) Analysis.

    abstract：INTRODUCTION:Patients with stage I small cell lung carcinoma (SCLC) are candidates for surgery; however, not much is known regarding the utilization of surgical resection in the management of stage I SCLC and the factors that determine the patient's ability to receive surgery. METHODS:The Surveillance, Epidemiology an...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2017.03.003

    authors： Ahmed Z,Kujtan L,Kennedy KF,Davis JR,Subramanian J

    更新日期：2017-09-01 00:00:00

  • Clinical significance of downstaging in patients with limited-disease small-cell lung cancer.

    abstract：BACKGROUND:We investigated the effect of downstaging on OS in LD-SCLC patients treated with first-line treatment. PATIENTS AND METHODS:We retrospectively reviewed 210 LD-SCLC patients who were treated with first-line treatment at Seoul National University Hospital between April 1999 and November 2012. Compared with in...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.09.003

    authors： Go SI,Keam B,Kim TM,Lee SH,Kim DW,Kim HJ,Wu HG,Chung DH,Heo DS

    更新日期：2014-03-01 00:00:00

  • Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity.

    abstract：:Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic dermatologic side effects. Skin rash is the dose-limiting factor for all EGFR inhibitors and is usually dose related and reversible. Microbiologic stains and cultures from skin rash usually do not show an infectious cause. We re...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2008.n.010

    authors： Grenader T,Gipps M,Goldberg A

    更新日期：2008-01-01 00:00:00

  • Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.

    abstract：PURPOSE:This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was allowed. Patients received gemcitabine 3000 mg/m(2) intravenously over 30 minutes and paclitaxel 15...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2007.n.010

    authors： Wozniak AJ,Belzer K,Heilbrun LK,Kucuk O,Gadgeel S,Kalemkerian GP,Venkatramanamoorthy R,Kraut MJ

    更新日期：2007-03-01 00:00:00

  • Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials.

    abstract：BACKGROUND:Afatinib is approved in the US, Europe, and several other regions for first-line treatment for epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS:Treatment-naive patients with advanced EGFRm+ NSCLC were randomized to afatinib (40 mg/d) versus...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2018.03.009

    authors： Wu YL,Sequist LV,Tan EH,Geater SL,Orlov S,Zhang L,Lee KH,Tsai CM,Kato T,Barrios CH,Schuler M,Hirsh V,Yamamoto N,O'Byrne K,Boyer M,Mok T,Peil B,Märten A,Chih-Hsin Yang J,Paz-Ares L,Park K

    更新日期：2018-07-01 00:00:00

  • Effect of Thoracic Radiotherapy Timing and Fractionation on Survival in Nonmetastatic Small Cell Lung Carcinoma.

    abstract：BACKGROUND:The optimal timing of thoracic radiation therapy (RT) in relation to chemotherapy is unknown in the treatment of nonmetastatic small cell lung cancer (SCLC). We analyzed the National Cancer Data Base (NCDB) to assess the effect on overall survival (OS) of RT timing with chemotherapy for patients with SCLC. ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.07.009

    authors： Wong AT,Rineer J,Schwartz D,Becker D,Safdieh J,Osborn V,Schreiber D

    更新日期：2017-03-01 00:00:00

  • The Role of Performance Status in Small-Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors.

    abstract：:After decades of platinum-based chemotherapy for advanced small-cell lung cancer, there has finally been a therapeutic advance. The combination of a platinum chemotherapy, etoposide, and an immune checkpoint inhibitor has yielded overall survival benefits in two successive phase 3 trials. Unfortunately, these trials o...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.04.006

    authors： Friedlaender A,Liu SV,Passaro A,Metro G,Banna G,Addeo A

    更新日期：2020-11-01 00:00:00

  • Management of Central Nervous System Metastases in Patients With Advanced Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer During Crizotinib Treatment.

    abstract：BACKGROUND:Central nervous system (CNS) progression is a common manifestation of acquired resistance to crizotinib in anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). However, an optimal tailored treatment approach has not been established in patients with CNS failure during crizotinib tr...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2019.06.013

    authors： Zhao Y,Zhang B,Wang S,Qiao R,Xu J,Zhang L,Zhang Y,Han B

    更新日期：2019-11-01 00:00:00

  • Role of topoisomerase I inhibitors in small-cell lung cancer.

    abstract：:Lung cancer continues to be the leading cause of cancer-related death in the United States. Small-cell lung cancer constitutes 15%-20% of all cases of lung cancer. It is a chemosensitive disease with an overall response rate of 70%-90% in first-line treatment. However, the majority of patients relapse, and further tre...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2001.n.010

    authors： Shihabi S,Belani CP

    更新日期：2001-05-01 00:00:00

  • Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

    abstract：BACKGROUND:It is unclear what proportion of VTE events in lung cancer patients are incidentally discovered and whether incidental events affect mortality. PATIENTS AND METHODS:We conducted a retrospective cohort study of lung cancer patients seen at the University of Rochester between January 1, 2006 and December 31, ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2013.06.003

    authors： Connolly GC,Menapace L,Safadjou S,Francis CW,Khorana AA

    更新日期：2013-11-01 00:00:00

  • Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a Real-life Limited-disease Small-cell Lung Cancer Patient Cohort Comprehensively Staged With Cranial Magnetic Resonance Imaging.

    abstract：INTRODUCTION:Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival. PATIENTS AND METHODS:The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and compl...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2016.11.005

    authors： Eze C,Roengvoraphoj O,Niyazi M,Hildebrandt G,Fietkau R,Belka C,Manapov F

    更新日期：2017-07-01 00:00:00

  • Phase II trial of neoadjuvant chemotherapy using alternating doublets in non-small-cell lung cancer.

    abstract：PURPOSE:Lung cancer is an epidemic disease in developing countries. Incorporation of new active drugs in the neoadjuvant treatment of operable patients might lead to improved outcomes. Postchemotherapy mediastinal-based treatment decisions allow for in vivo testing of activity and could help to determine the ideal loca...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/CLC.2007.n.003

    authors： Martins RG,Dienstmann R,de Biasi P,Dantas K,Santos V,Toscano E,Roriz W,Zamboni M,Sousa A,Small IA,Moreira D,Ferreira CG,Zukin M

    更新日期：2007-01-01 00:00:00

  • Incidental Diagnosis of Asymptomatic Non-Small-Cell Lung Cancer: A Registry-Based Analysis.

    abstract：INTRODUCTION:Clinical manifestation of non-small-cell lung cancer (NSCLC) mainly occurs at advanced stages. Thus, the scientific community is evaluating different screening programs in high-risk patients to detect NSCLC at an earlier stage to improve survival. However, up to now patient selection and modalities have be...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2015.08.006

    authors： Kocher F,Lunger F,Seeber A,Amann A,Pircher A,Hilbe W,Fiegl M

    更新日期：2016-01-01 00:00:00

  • Quality of life and the treatment of advanced lung cancer.

    abstract：:Lung cancer is the leading cause of cancer deaths worldwide, with the majority of patients presenting with advanced disease. Despite the introduction of newer therapeutic agents and modest survival improvement, the overall prognosis for these patients is poor. The goals of therapy should therefore include improvement ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.3816/CLC.2003.n.018

    authors： Plunkett TA,Chrystal KF,Harper PG

    更新日期：2003-07-01 00:00:00

  • Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy.

    abstract：INTRODUCTION:In the phase III LUX-Lung 8 trial, afatinib significantly improved progression-free survival (PFS) and overall survival (OS) versus erlotinib in patients with squamous cell carcinoma (SCC) of the lung progressing during or after platinum-based chemotherapy. Patient-reported outcomes (PROs) and health-relat...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,随机对照试验

    doi：10.1016/j.cllc.2017.06.002

    authors： Felip E,Hirsh V,Popat S,Cobo M,Fülöp A,Dayen C,Trigo JM,Gregg R,Waller CF,Soria JC,Goss GD,Gordon J,Wang B,Palmer M,Ehrnrooth E,Gadgeel SM

    更新日期：2018-01-01 00:00:00

  • Aberrant promoter methylation of CDH13 and MGMT genes is associated with clinicopathologic characteristics of primary non-small-cell lung carcinoma.

    abstract：UNLABELLED:Non–small-cell lung carcinoma (NSCLC) (n = 65) were analyzed for promoter methylation of RASSF1A, CDH13, MGMT, ESR1, and DAPK genes in matching lung tumors, normal lung tissue, and blood samples. Aberrant methylation in CDH13 and MGMT was associated with clinicopathologic features of NSCLC. Hypermethylation ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.11.003

    authors： Kontic M,Stojsic J,Jovanovic D,Bunjevacki V,Ognjanovic S,Kuriger J,Puumala S,Nelson HH

    更新日期：2012-07-01 00:00:00

  • Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer.

    abstract：BACKGROUND:First-line treatment of non-small-cell lung cancer (NSCLC) has undergone a paradigm shift to platinum combination therapy together with an immune checkpoint inhibitor (ICI). Bevacizumab is expected to enhance not only chemotherapy but also the efficacy of ICIs through blockade of vascular endothelial growth ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2020.03.010

    authors： Shiraishi Y,Kishimoto J,Tanaka K,Sugawara S,Daga H,Hirano K,Azuma K,Hataji O,Hayashi H,Tachihara M,Mitsudomi T,Seto T,Nakagawa K,Yamamoto N,Okamoto I

    更新日期：2020-09-01 00:00:00

  • Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.

    abstract：:The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章,评审

    doi：10.1016/j.cllc.2018.12.019

    authors： Pacheco J,Bunn PA

    更新日期：2019-05-01 00:00:00

  • Costs and ethical issues related to first-line treatment of metastatic non-small-cell lung cancer: considerations from a public healthcare system perspective.

    abstract：:Metastatic non-small-cell lung cancer is generally not considered to be curable, and the overall 5-year survival rate is less than 1%. Despite this poor prognosis, palliative chemotherapy can increase time and quality of life in the advanced-disease setting. New chemotherapy treatments and targeted therapies are avail...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.1016/j.cllc.2011.06.007

    authors： Bosch-Barrera J,Quer N,Brunet J

    更新日期：2011-11-01 00:00:00

  • Phase II study of sequential treatment of advanced non-small-cell lung cancer: three cycles of high-dose epirubicin plus cisplatin followed by weekly vinorelbine.

    abstract：:Previous phase I, II, and III studies on high-dose epirubicin (HDEPI), alone or in combination with cisplatin (CP), indicate an interesting activity of this drug in the treatment of non-small-cell lung cancer (NSCLC). However, the toxicological profile of HDEPI limits its prolonged use. In our experience, vinorelbine ...

    journal_title：Clinical lung cancer

    pub_type： 杂志文章

    doi：10.3816/clc.2001.n.017

    authors： Guaraldi M,Marino A,Pannuti F,Farabegoli G,Martoni A

    更新日期：2001-08-01 00:00:00